20686-40-2

Basic information

• Product Name: 4-(acetylamino-methyl)-benzoic acid methyl ester
• Synonyms: 4-(acetylamino-methyl)-benzoic acid methyl ester
• CAS NO: 20686-40-2
• Molecular Weight: 207.229
• Mol File: 20686-40-2.mol

Chemical Properties

• CAS DataBase Reference: 4-(acetylamino-methyl)-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(acetylamino-methyl)-benzoic acid methyl ester(20686-40-2)
• EPA Substance Registry System: 4-(acetylamino-methyl)-benzoic acid methyl ester(20686-40-2)

Safety Data

• Hazardous Substances Data: 20686-40-2(Hazardous Substances Data)

Upstream product

• 18469-52-8 methyl 4-(aminomethyl)benzoate 
• 1205-58-9 4-[(Acetylamino)methyl]-benzoic acid 
• 42967-55-5 monomethyl monopotassium terephthalate 
• 120-61-6 1,4-benzenedicarboxylic acid dimethyl ester 
• 7377-26-6 4-Methoxycarbonylbenzoyl chloride 
• 1129-35-7 4-cyanobenzoic acid methyl ester 
• 108-24-7 acetic anhydride 
• 6232-11-7 methyl 4-(aminomethyl)benzoate hydrochloride 
• 75-36-5 acetyl chloride 
• 56-91-7 p-aminomethylbenzoic acid 
• 67-56-1 methanol 

Downstream Products

• 51782-10-6 methyl 4-(acetamidomethyl)cyclohexane-1-carboxylate 
• 136869-07-3 N-acetyl(4-hydroxymethyl)benzylamine 
• 223512-58-1 methyl 4-acetamidomethyl-3-nitrobenzoate 
• 223511-24-8 N-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenylmethyl)acetamide 
• 223512-42-3 N-(4-((4-phenylpiperazin-1-yl)methyl)phenylmethyl)acetamide 
• 223512-41-2 N-(4-chloromethyl-benzyl)-acetamide 

Relevant articles and documents

An improved and practical synthesis of tranexamic acid

Tranexamic acid 1, a synthetic antifibrinolytic drug with the treatment being considered highly cost-effective in many countries, has been included in the WHO list of essential medicines. In this paper, we designed the synthesis of 1 via a novel seven-step route from the readily available starting material dimethyl terephthalate, performing with 99.6% purity in 59.2% overall yield. During the process, we successfully developed a direct and efficient method for the preparation of key intermediate methyl 4-(acetamidomethyl)benzoate by one-pot hydrogenation and acylation in acetic anhydride using Ni/Al2O3 as a catalyst. More importantly, it should be a straightforward and practical way to circumvent the usage of toxic reagents (CrO3, Cl2), solvent (CCl4), and expensive catalyst (PtO2), etc., that plagued the previous methodologies.

Rapid and Selective Cleavage of Amide Groups at Neutral pH: Applications from Hyaluronic Acid to Small Molecules

During our investigation to find suitable conditions to prepare very high molecular weight partially de-acetylated hyaluronic acid (HA), we discovered a powerful new method to cleave amide bonds using hydroxylamine salts at neutral pH with remarkable sele

A 4-acetamidomethyl methyl cyclohexyl method for producing methyl formate

The invention relates to a preparation method of methyl 4-acetylaminomethyl hexahydrobenzoate. The method comprises the following steps: adding methyl paracyanobenzoate into a reaction kettle, adding a metal catalyst I and a cocatalyst II, heating while stirring to react under hydrogen gas conditions for 6-10 hours by using acetic anhydride as a solvent, filtering, and distilling to obtain the methyl acetylaminomethyl benzoate; and adding the obtained methyl acetylaminomethyl benzoate into a reaction kettle, adding a solvent V, a metal catalyst III and a cocatalyst IV, heating while stirring to completely react under hydrogen gas conditions, filtering, and distilling to recover the solvent, thereby obtaining the methyl 4-acetylaminomethyl hexahydrobenzoate. The synthesis technique of preparing the methyl 4-acetylaminomethyl hexahydrobenzoate from the initial raw material methyl paracyanobenzoate has the advantages of accessible raw materials, low cost, high yield and the like, and is simple to operate and suitable for industrial production. The product can be further used for preparing the trans-4-aminomethylcyclohexyl formic acid, and has huge application potential.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

Compounds useful as reversible inhibitors of cysteine proteases

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.

Imidazole derivatives

The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof. The compounds of the formulas (I) and (XII) and pharmaceutically acceptable salts thereof of the present invention inhibit IL-4 and IL-5 production by Th2 cells and are effective for the prophylaxis and treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis and the like.

Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity

Phenylpiperazine derivatives were synthesized as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity. Lead optimization led to compound 5k having the potent regulatory activity and demonstrating remarkable protective effects against the lethal challenge of LPS in mice, suggesting that 5k would be a promising drug candidate for the treatment of TNF-α associated diseases including septic shock. (C) 2000 Elsevier Science Ltd. All rights reserved.